The o2h human health EIS fund is our flag-ship fund and was the first HMRC approved Knowledge-intensive fund that will invest in EIS qualifying knowledge-intensive companies. The o2h human health funds invest in early stage biotech therapeutic companies focused on novel drug discovery along with enabling services, tools and AI technologies that can support new medicines. To support the Government’s aim to strengthen and grow UK innovation, which was known to be capital and research-intensive, the EIS knowledge-intensive fund has been launched to pledge support to companies working in this space, providing them access to capital to develop their early novel ideas.
o2h Ventures was launched in 2018 to provide pre-seed and seed capital to Great British biotech innovations. To date the fund and pre-fund has invested into over 35 companies, several of which have now raised significant funds from overseas, listed and built game changing drugs to benefit human health.
The o2h team are leaders in the Biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grass-roots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating emerging Biotech therapeutic companies.
Investing in a Knowledge-intensive EIS fund will provide greater predictability of the year in which EIS relief can be claimed as well as other benefits over and above investing in a non HMRC compliant EIS fund. We have two closes per year and the next one is on 5th April 2022.
The minimum investment is £25k.* For more information, please visit https://o2hventures.com/funds/the-o2h-human-health-ki-eis-fund
